Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in the fast ...

Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...

Cantor analysts cited early data suggesting bone safety risk Amgen confident in drug's profile, plans to release mid-stage study data later this year Amgen shares partially recover after a 7% ...

Amgen said there is no link between its experimental weight loss drug, MariTide, and changes in bone density. The statement comes a day after that potential safety concern wiped off more than $12 ...

Shares of Amgen fell as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. While some analysts called the additional data a ...

(RTTNews) - Amgen Inc. (AMGN) Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes in bone mineral density. Following the news ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an analyst at Cantor Fitzgerald, focused on ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the ...